Immunocore(IMCR)

Search documents
Immunocore(IMCR) - 2024 Q3 - Quarterly Results
2024-11-06 12:22
Exhibit 99.1 Immunocore reports third quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $80.2 million in 3Q 2024, 28% growth over 3Q 2023 Phase 3 trials in cutaneous melanoma ongoing (PRISM-MEL-301 and TEBE-AM); and Phase 3 trial in adjuvant uveal melanoma (ATOM) to start randomizing in 4Q 2024 Presented Phase 1 brenetafusp data in platinum-resistant ovarian cancer patients; ongoing signal detection in metastatic NSCLC will shift initial data release; focu ...
Immunocore(IMCR) - 2024 Q3 - Quarterly Report
2024-11-06 12:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-39992 Immunocore Holdings plc (Exact name of registrant as specified in its charter) | --- | --- | |-------- ...
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
GlobeNewswire News Room· 2024-09-14 07:00
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer Brenetafusp is clinically active as monotherapy and in combination with chemotherapy in heavily pretreated, platinum-resistant ovarian cancer patients T cell fitness gene expression signature in blood is an important parameter of clinical activity for tebentafusp in uveal melanoma and for brenetafusp across different tumor types (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., ...
Immunocore: Pipeline Expands HLA Tumor Targeting Beyond Kimmtrak
Seeking Alpha· 2024-08-30 15:40
Bevan Goldswain/E+ via Getty Images Immunocore (NASDAQ:IMCR) has made significant progress in being able to use its proprietary ImmTAX platform to develop T-cell receptors [TCRs] against a variety of types of cancer. It has already received FDA approval of Kimmtrak for the treatment of patients with advanced or metastatic uveal melanoma who are HLAA*02:01-positive. Sales for this drug franchise continue to climb, especially when you consider the reported number. It was stated that in Q2 of 2024, sales of Ki ...
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
Newsfilter· 2024-06-18 11:00
First registrational Phase 3 trial investigating PRAME-targeted therapy "We are very proud to have started the registrational program for brenetafusp, our PRAME candidate, supported by the recent promising brenetafusp monotherapy data in late-line cutaneous melanoma" said Mohammed Dar, Senior Vice President, Clinical Development, and Chief Medical Officer, Immunocore. "The PRISM-MEL301 trial – the first Phase 3 trial for any PRAME-targeted therapy – will test whether combining brenetafusp with nivolumab may ...
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
Newsfilter· 2024-06-01 12:00
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response Data were presented at ASCO 2024, where Immunocore also presented Phase 1 data from its PRAME trial with brenetafusp (IMC-F106C) in advanced cutaneous melanoma "In both Phase 2 and Phase 3 KIMMTRAK trials, patients with stable disease and durable tumor reduction, regardless of depth, had similar benefit as patients with RECI ...
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
Newsfilter· 2024-05-31 20:05
Core Insights - Immunocore has reported updated Phase 1 data for brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, showing promising clinical activity in late-line cutaneous melanoma patients previously treated with immune checkpoint inhibitors [1][2][3] Phase 1 Clinical Data - Monotherapy with brenetafusp demonstrated a disease control rate (DCR) of 56%, with 4 patients achieving partial response (ORR 11%) and 16 patients showing stable disease [6] - The median progression-free survival (mPFS) for all patients was 4.2 months, with a notable difference in mPFS between PRAME positive (4.2 months) and PRAME negative patients (2.1 months) [7] - Among ctDNA-evaluable PRAME positive patients, 42% exhibited a molecular response, while no PRAME negative patients showed ctDNA reduction [7] Patient Population and Treatment Tolerance - A total of 47 patients received brenetafusp monotherapy, all of whom had prior exposure to immune checkpoint inhibitors, with 100% having received anti-PD1 and 81% anti-CTLA4 [4] - Brenetafusp was well tolerated, with manageable treatment-related adverse events (TRAEs) primarily consisting of Grade 1 or 2 cytokine release syndrome (CRS) and rash [5][8] Combination Therapy Insights - In a cohort of 9 patients receiving brenetafusp in combination with anti-PD1 (pembrolizumab), 4 achieved disease control, including 1 ongoing partial response [9] - The combination therapy was also well tolerated, with manageable TRAEs consistent with the mechanisms of both agents [8] Gene Expression and T Cell Fitness - A gene signature indicating systemic T cell fitness was identified, with patients above the median expression level showing a median PFS of 6 months and a DCR of 69% compared to 2 months and 42% for those below the median [10] Upcoming Trials and Presentations - Immunocore is currently enrolling patients in a Phase 3 clinical trial (PRISM-MEL-301) for brenetafusp combined with nivolumab in first-line advanced cutaneous melanoma, with the primary endpoint being progression-free survival [12][17] - The advanced cutaneous melanoma data from the ongoing Phase 1/2 trial will be presented at the 2024 ASCO Annual Meeting [11]
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
Newsfilter· 2024-05-29 11:00
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma Following recent consultation with FDA, all patients randomized from start of TEBE-AM Phase 2/3 trial will be included in the Phase 3 intent-to-treat population Phase 3 will continue three arms: KIMMTRAK monotherapy, KIMMTRAK in combination with pembrolizumab, and control Expected to accelerate time to final Phase 3 overall survival analysis (OXFORDSHI ...
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
globenewswire.com· 2024-05-29 11:00
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma Following recent consultation with FDA, all patients randomized from start of TEBE-AM Phase 2/3 trial will be included in the Phase 3 intent-to-treat population Phase 3 will continue three arms: KIMMTRAK monotherapy, KIMMTRAK in combination with pembrolizumab, and control Expected to accelerate time to final Phase 3 overall survival analysis (OXFORDSHI ...
Immunocore(IMCR) - 2024 Q1 - Quarterly Results
2024-05-08 11:13
Exhibit 99.1 Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $70.3 million in Q1 2024; continuing to expand global access with 7 additional launches since January 2024 Phase 1/2 brenetafusp (IMC-F106C; PRAME-A02) clinical data in post-checkpoint late-line cutaneous melanoma selected for oral presentation at ASCO 2024 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, May 8, 2024) Immunocore Holdings plc (Nasdaq: IM ...